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Abstract: Throughout the last decade, efforts to identify and develop effective inhibitors of 
the ricin toxin have focused on targeting its N-glycosidase activity. Alternatively, 
molecules disrupting intracellular trafficking have been shown to block ricin toxicity. 
Several research teams have recently developed high-throughput phenotypic screens for 
small molecules acting on the intracellular targets required for entry of ricin into cells. 
These screens have identified inhibitory compounds that can protect cells, and sometimes 
even animals against ricin. We review these newly discovered cellular inhibitors of ricin 
intoxication, discuss the advantages and drawbacks of chemical-genetics approaches, and 
address the issues to be resolved so that the therapeutic development of these small-molecule 
compounds can progress. 
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1. Why Target Cellular Components? A Chemical Genetics Approach 
Ricin toxin is a lectin produced in the seed of the plant Ricinus communis. This plant is used for 
ornamentation, but also has a high industrial value for the oil contained in the seed. The oil enters in 
the composition of brake fluids, soaps, shampoos, cosmetics and paints. However, the hydrophilic 
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toxin remains in the crushed seeds from which it can be easily purified. Its lethal dose is a  
few µg per kg when injected in mice and between 1 and 20 mg if ingested in humans. Public 
authorities consider ricin as a potential bio-crime and bio-terrorist weapon for which there is absolutely 
no specific antidote. In addition, ricin has been used for the design of immunotoxins against tumor 
cells, although non-specific toxicity prevented those to reach approval for cancer therapy. To counter 
the threat displayed by the plant toxin ricin, several therapeutic approaches have been developed. One 
approach is the use of vaccination to elicit the production of neutralizing antibodies that inactivate ricin  
in vivo [1,2]. However, it is unrealistic to perform a mass vaccination program to protect whole 
populations against ricin. Another approach is to design new antitoxins. However, although 
neutralizing antibodies are effective in animal models [3,4], they are of limited use in clinical practice 
due to their cost and limited therapeutic window. So far, the catalytic activity of the enzymatic moiety 
of ricin (the A chain, termed RTA) has been the target of choice for inhibition by small-molecule 
compounds such as transition-state analogues [5] based on pterin and purine scaffolds [6–8], or nucleic 
acid ligands [9–11]. Such enzymatic inhibitors have been identified by virtual screens or by in vitro 
selection [8,11–13]. Although active in enzymatic tests, they usually fail to protect cells or animals 
against a ricin challenge. There is only one published report of an anti-ricin A-chain RNA aptamer 
(31RA) that protects cells against ricin exposure [10]. 
Alternatively, few molecules altering intracellular trafficking have been shown to block ricin 
toxicity. However, the dramatic effect of these compounds on the integrity of the Golgi apparatus does 
not allow their development for therapy. Screening for small-molecule inhibitors of cellular targets is a 
complementary means of identifying bioactive compounds against ricin. This approach is often termed 
chemical genetics, and focuses on the identification of new pharmacological targets and chemical 
scaffolds that show the desired activity on cells. RNAi-based screening, another possible strategy to 
identify cell proteins involved in ricin toxicity, will not be discussed here. Cell-based assays do not 
exclusively aim to identify enzymatic inhibitors. Other targetable pathways, which are investigated, 
include: binding to cell-surface receptors, internalization, intracellular trafficking, dissociation of the 
catalytic RTA from the receptor-binding B chain (termed RTB), and retro-translocation of RTA across 
the ER membrane to the cytosol. Another advantage of cell-based assays is the ability to monitor the 
toxicity and cell permeability of inhibitors in the same system used for the screening process. 
Cell-based high-throughput screening (HTS) studies have been used by research teams to identify 
inhibitors that can protect cells against toxins such as ricin and Shiga toxin [14–16]. Ricin and the 
bacterial Shiga toxin share several characteristics. They have one moiety (the B chain or B-subunit) 
that binds to their respective cellular receptors (glycoproteins and glycolipids for ricin; the 
glycosphingolipid Gb3 for Shiga toxins), while another moiety (the A chain or A-subunit) enters the 
cytosol and inactivates protein synthesis. Both toxins are transported in a retrograde manner from the 
plasma membrane to the endoplasmic reticulum (ER) [17], before translocation to the cytosol where 
they enzymatically inactivate the 28S RNA of the 60S ribosomal subunit (reviewed in [17–20]. It is 
therefore likely that inhibitors acting on the intracellular routing of Shiga toxins will also interrupt the 
trafficking of ricin. This review on ricin will thus also discuss compounds mentioned in Section 2 that 
have been described as Shiga-toxin inhibitors. Phenotypic screening approaches based on inhibition of 
protein biosynthesis in mammalian cells have provided a robust platform for analyzing libraries in 
chemical-genetic studies, and have been used to identify ricin inhibitors (Figure 1). In an initial study 
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by Saenz et al., a luciferase-based assay was used to screen 14,400 molecules and identified two 
compounds that protected monkey Vero cells from the cytotoxic effects of Shiga toxin and ricin [16]. 
The methodology involved transfection of cells with cDNA encoding a destabilized luciferase with a 
short half-life. Thus, cells treated with toxin showed a rapid decrease in luciferase activity. The two 
compounds identified showed a marked potency and selectivity against intracellular toxin transport. 
Figure 1. High-throughput cell-based assays. These phenotypic assays measure the effects 
of small-molecule compounds on cellular cytotoxicity induced by ricin. (a) Chemical 
compounds are distributed into microplates for screening. A small volume of each 
compound is then added to a well of a microplate seeded with cells. (b) After addition of 
toxin and incubation, one of several possible methods is used to assess the effects of each 
compound on the toxin-mediated inhibition of protein biosynthesis. (c) The CellTiter-Glo 
luminescent cell-viability assay quantifies ATP, which signals the presence of 
metabolically active cells. Luminescent signal is generated by the luciferase (green star) 
reaction after cell lysis and is proportional to the amount of ATP present [14]. In luciferase 
reporter-gene assays, a modified luciferase is constitutively transcribed, and enzyme 
activity is used as a measure of ongoing protein biosynthesis. Inhibition of protein 
biosynthesis thus leads to diminish luciferase translation, and as existing luciferase protein 
is degraded there is a proportional decrease in light output [21]. In the third method of 
assessment, the inhibitory effect of ricin on protein biosynthesis in intact cells is measured 
through the incorporation of radioactive amino acids into neosynthesized polypeptides. 
Intact cells are able to concentrate the amino acid that strikes the incorporated scintillant 
molecules present in the bottom of each well (bold line) in the microplate [15]. 
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Finally, Stechmann et al. have used a protein biosynthesis assay to screen the effects of 16,480 
molecules from a commercial library of drug-like compounds on A549 human epithelial pulmonary 
cells [15]. Several ricin inhibitors were identified, and two of these were studied in further detail. Both 
inhibitors selectively block retrograde toxin trafficking at the early endosome/trans-Golgi network 
(TGN) interface. One compound protected mice exposed to a lethal dose of ricin administered by  
nasal instillation.  
2. Inhibitors of Retrograde Transport Toxins that Act Inside Cells 
2.1. Compounds that Target an Identified Host Target 
Characterization of molecules that protect cells against ricin by blocking its intracellular trafficking 
has revealed compounds that often alter the morphology of the Golgi apparatus. This limits their 
therapeutic interest due to potentially strong side effects. 
Ilimaquinone (IQ, MW: 358.5, Figure 2a) is a sesquiterpenoid quinone metabolite isolated from 
marine sponges. IQ inhibits the cytotoxicity of ricin on Vero cells in a dose-dependent manner [22]. 
This inhibition is reversed when IQ is removed from the culture medium. IQ causes breakdown of the 
Golgi apparatus and its fragmentation into small vesicular structures [23,24]. This is likely because IQ 
interacts with enzymes of the activated methyl cycle such as S-adenosylmethionine synthetase,  
S-adenosylhomocysteinase, and methyl transferases [25]. Although some authors have suggested that 
IQ has an effect on small GTPases, no direct evidence for this property has been reported. 
Brefeldin A (BFA, MW: 280.4, Figure 2a) is an isoprenoid fungal metabolite that inhibits ricin 
toxicity in vitro and protects cells from the cytotoxic effects of ricin and Shiga toxin [26–28]. BFA 
disrupts the structure and function of the Golgi apparatus, and strongly impairs intracellular protein 
transport and secretion [29]. Although BFA protects a number of cell lines against ricin, some cell 
lines such as the MDCK and PtK2 kidney epithelial cell lines, are sensitized to ricin [30]. These 
differential effects of BFA are probably due to variations in the structural organization of the Golgi 
apparatus among the different cell lines. BFA inhibits the activation and function of the  
ADP-ribosylation factor (Arf) family by inhibiting specific guanine nucleotide exchange factors 
(GEFs) [31]. GEFs regulate Arf GTPase by accelerating the nucleotide exchange from its inactive 
GDP-bound form to its active GTP-bound form, which can interact with effectors [32,33]. Golgi-localized 
Arf1 is present in eukaryotic cells and regulates anterograde and retrograde traffic [34,35]. Arf1 
recruits the coatomer complex at the cis-Golgi network to assemble COPI-coated vesicles, whereas 
clathrin adaptor proteins are recruited at the trans-Golgi network and on endosomes. The cis-Golgi 
localized GEF, Golgi BFA resistance factor 1 (GBF1), and the trans-Golgi localized GEFs, Brefeldin 
A-inhibited GEP 1 (BIG1) and Brefeldin A-inhibited GEP 2 (BIG2) which share a Sec7 domain 
required for guanine nucleotide exchange, are sensitive to BFA (Figure 3). Activation of Arf1 by 
GBF1 mediates COPI coat recruitment and enables transport of vesicles between the ER and the Golgi 
apparatus [36]. Activation of BIG1 and BIG2 leads to Arf1-recruitment of clathrin adaptors, such as 
AP-1, AP-3, and AP-4, which mediate transport between the Golgi and endosomal compartments [37]. 
More precisely, the BFA targets the complex between Arf-GDP and the catalytic domain (the sec7 
domain) of an ArfGEF at the beginning of the exchange reaction. BFA binds to the interface between 
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Arf-GDP and ArfGEF and blocks the complex in an abortive conformation that cannot proceed to 
GDP/GTP exchange [32]. BFA is by far one of the best-characterized GEF inhibitors; this 
characterization has taken approximately 40 years since its discovery as a natural product. 
Understanding the mechanism of action of BFA has led to the general concept of interfacial inhibition. 
This refers to inhibitors that trap macromolecules in transition states with their partners near 
interacting interfaces in dead-end complexes which are unable to complete their biological role. 
Furthermore, the resistance to BFA in some cell lines, such as canine MDCK, has been related to a 
single amino-acid substitution (M832L) within the Sec7 domain of GBF1, which modifies its 
interaction with BFA [32,38,39]. Nevertheless, the high toxicity of BFA precludes its use as a 
pharmaceutical treatment for ricin poisoning. 
The compound Golgicide A (GCA, MW: 284.3) was identified by Saenz et al. in a HTS study of 
small molecules that inhibited the effects of bacterial toxins on host cells [39]. When used at a 
concentration of 10 µM, GCA strongly protects Vero cells from Shiga toxin. GCA is a potent and 
reversible inhibitor of the cis-Golgi ArfGEF, GBF1, but has no effect on BIG1 and BIG2 (cf. Figure 
3). GCA also causes complete dispersal of the medial-Golgi marker, giantin and the cis-Golgi marker, 
GM130. As observed with BFA, mutagenesis and molecular-modeling studies show that GCA binds at 
the interface of Arf1 and GBF1 Sec7 domain [39]. Inhibition of GBF1 results in the dissociation of the 
COPI vesicle coat from the Golgi membranes and subsequent disassembly of the Golgi and  
trans-Golgi networks. 
Exo2 (MW: 354.4) was first identified in chemical genetics studies of inhibitors of the secretory 
pathway [40,41]. This compound rapidly blocks anterograde traffic from the ER to the Golgi apparatus, 
and selectively disrupts the Golgi apparatus. Exo2 was then used as a pharmaceutical tool to study the 
function of the Golgi apparatus in retrograde toxin trafficking [42,43]. These studies showed that Exo 
2 has no effect on trafficking of cholera toxin from the cell surface to the ER [42], but significantly 
inhibits the delivery of Shiga-toxin to the ER [43]. Similar to BFA, Exo2 disrupts the morphology of 
the TGN [43]. However, in contrast with BFA, Exo2 does not induce tubulation and fusion of the TGN 
and endosomal membranes [43]. Furthermore, treatment with Exo2 dissociates COPI, but leaves AP-1 
intact. This may be because Exo2 selectively inhibits GBF1 as a primary target among the ArfGEFs 
(cf. Figure 3). However, even if Exo2 inhibits Arf-GEF function, the other phenotypic changes induced 
by Exo2 may be unrelated to its effects on GBF1 [44]. 
The Exo2 derivative, LG186 (MW: 382.5), was synthesized to enhance selectivity for GBF1 [44]. 
Compared with Exo2, LG186 has a cyclo-octenyl ring instead of a cyclohexenyl ring within a tricyclic 
structure, but is otherwise identical (cf. Figure 2). Although BFA, GCA, and Exo2 do not perturb the 
Golgi complex in MDCK cells, LG186 removes COPI from vesicle membranes and induces a collapse 
of the Golgi complex [44]. Molecular-modeling studies suggest that the cyclo-octenyl ring of LG186 
compensates for the loss of interaction of the M832L residue of GBF1 with GCA, BFA, and Exo2 in 
MDCK cells. However, LG186 appears to have a residual inhibition of other ArfGEFs. Other derivatives 
of Exo2 have also been designed to conserve the protective effects of Exo2 against Shiga toxin and to 
decrease its cytotoxicity [45,46]. Exo2 and its derivatives have therefore provided more selective tools 
than BFA to decipher membrane trafficking in mammalian cells. 
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Figure 2. Chemical structures of the known cellular inhibitors of ricin and Shiga toxins. (a) 
Structures of inhibitors with a known molecular target; (b) Structure of inhibitors identified 
by cellular high-throughput screening whose cellular targets are currently unidentified. The 
CID number is the Chemical IDentifier for molecular structures in PubChem. References 
for the molecules are given in the text. 
 
2.2. Compounds with Unknown Molecular Targets 
Two compounds, named 75 (MW: 398.3) and 134 (MW: 276.4) which protect Vero cells from  
the cytotoxic effects of ricin and Shiga toxin, have been identified in a cellular HTS study by  
Saenz et al. [16] (cf. Figure 2b). The protective effects of these compounds results from their 
disruption of intracellular transport at distinct steps along the retrograde toxin-trafficking pathway. The 
maximal protective effects against cytotoxicity are observed at a concentration of 50 µM for 
compound 75, and 100 µM for compound 134. Compound 75 protects Vero cells against Shiga toxin, 
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ricin, as well as diphtheria toxin (DT), whereas compound 134 is inactive against DT. DT is released 
into the cytosol from endosomes after a translocation step at low pH. The lack of protection against DT 
by compound 134 thus suggests that this inhibitor acts only after the early endosome stage. In contrast, 
compound 75 is likely to act during the very early events of endocytosis. Fluorescence microscopy 
analysis revealed the presence of STxB in the early endosomes of cells treated with compound 75 [16]. 
In contrast, STxB reaches the perinuclear recycling endosomes of cells treated with compound 134. 
Neither compound affects the binding or endocytosis of STxB, nor do they inhibit anterograde 
transport between ER-to-Golgi. However, in contrast with compound 134, compound 75 partially 
blocks secretion from the TGN. Both compounds induce morphological changes to the Golgi 
apparatus, and their effects are reversible. Sulfation assays (for further details, see [47]) demonstrated 
that the trafficking of toxins to the TGN is reduced by 53% with compound 75, and by 28% with 
compound 134. Compound 75 thus appears to inhibit transport at an early stage of endocytosis, 
whereas compound 134 appears to inhibit transport at a post-recycling endosome stage (cf. Figure 3). 
However, the targets of these two compounds are yet to be identified. It is nevertheless unlikely that 
either compound can be developed for therapeutic use due to their effects on the integrity of the Golgi 
apparatus, which is an essential compartment for cellular homeostasis. 
Wahome et al. [14] have identified four small-molecule inhibitors with significant dose-dependent 
anti-ricin activity and EC50 values ranging from 23 to 62 µM. These small-molecule inhibitors also 
have a low to moderate cytotoxicity. One compound appears to be an enzymatic inhibitor of RTA. The 
three others, named compound 2 (CID 644401; MW: 220.3), compound 3 (CID 57337931; MW: 
378.4), and compound 4 (CID 18576762; MW: 336.4) (cf. Figure 2b), most likely interfere indirectly 
with ricin cytotoxicity by acting on cellular processes rather than on the toxin itself. However, no  
in-depth characterization of these compounds has been performed, and putative targets are yet to  
be identified. 
Figure 3. Cellular targets of some inhibitors of ricin and/or Shiga toxins.  
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Stechmann and co-workers [15] have recently identified two compounds, Retro-1 (MW: 373.2) and 
Retro-2 (MW: 320.1) (cf. Figure 2b), which protect human cells against ricin and Shiga toxins. 
Morphological and quantitative biochemical trafficking assays show that Retro-1 and Retro-2 inhibit 
retrograde toxin transport between early endosomes and the TGN/Golgi complex (cf. Figure 3). Using 
a STxB variant, developed as a biochemical tool [47], cells treated with Retro-1 or Retro-2 showed an 
80% reduction of retrograde transport to the Golgi complex. Electron microscopy and confocal 
microscopy experiments demonstrated that STxB accumulates in the early endosomes of cells treated 
with Retro-1 or Retro-2. However, Retro-1 and Retro-2 are highly selective compared with other 
inhibitors, and thus lack toxicity. Neither compound has any effect on the TGN46 endogenous 
retrograde cargo proteins or on the cation-independent mannose 6-phosphate receptor (CI-MPR). 
Furthermore, the structural and functional integrity of all organelles tested, such as the Golgi complex, 
the early and late endosomes, and the ER, is preserved in cells exposed to Retro-1 and Retro-2. Other 
intracellular trafficking events that intersect with the early endosomes/TGN interface, such as 
endocytosis, endocytic recycling, and the biosynthetic/secretory pathways, are not affected by 
treatment with these compounds. Retro-1 and Retro-2 do not show any additive or synergistic effect, 
and it is therefore likely that they share a common target that is yet to be identified. Retrograde 
transport at the early endosomes/TGN interface is regulated by a large number of trafficking  
factors [17]. The location of 26 of these factors was studied in cells treated with Retro-1 and Retro-2. 
Only syntaxin-5 was relocalized within minutes of compound treatment, suggesting that this SNARE 
protein is a direct or indirect target of Retro-1 and Retro-2. Furthermore, Retro-2 completely protects 
mice exposed to a lethal ricin challenge, and is therefore a promising compound for further 
development as a drug acting on retrograde toxins. As Retro-2 has to be given prior to ricin exposure, 
the drug delivery pathways and pharmaceutical formulations need to be improved to maximize the 
benefits of this inhibitor. Nevertheless, the retrograde transport route is a potential therapeutic target in 
the development of broad-spectrum antibiotic compounds against pathogens or pathogenic products 
that use this pathway to gain entry into cells. 
3. Identifying Intracellular Protein-Binding Targets of Ricin Inhibitors 
The potential of phenotypic screens for the discovery of useful compounds against ricin toxicity is 
promising. However, this method requires the development of a structure-based rational drug-design to 
identify molecular targets. Identifying intracellular protein-binding targets of small-molecules is an 
integral part of chemical genetics. Identification of these targets during the early stages of drug 
discovery can help to address issues such as selectivity, toxicity, and off-target pharmacology. Indeed, 
hits can target any protein, which makes this identification process difficult and probably the most 
rate-limiting step in the development of useful compounds. The possibility of success in target 
identification greatly increases with binding affinity. However, much of the difficulty arises from 
weakly binding interactions between compounds identified in HTS and their cellular targets. Although 
nanomolar or lower binding constants make target identification feasible, in most cases inhibitors from 
screens have micro-molar activities [14–16]. Another difficulty in understanding of the mode of action 
of inhibitors is related to the use of cellular phenotypes as readouts, which often involve intricate 
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biological processes and interactions between various pathways. This level of complexity can present 
major challenges when characterizing the targets and mode of action of inhibitors. 
The classical approach to identify targets of inhibitors is based on affinity chromatography. This 
technique requires immobilization of the inhibitor (bait compound) to a solid support such as magnetic 
beads or beads for affinity chromatography, which can be achieved through a linker arm. Another 
possibility is introducing a reactive group (e.g., a photo-affinity label) that can be activated to crosslink 
with target proteins. Bait compounds can also have a detection tag such as a fluorescent moiety, 
radioactive tracer (e.g., 14C, or 3H), or biotin for non-covalent immobilization on streptavidin-coated 
beads. For target identification, it is essential to achieve these chemical modifications without 
interfering with the activity of the bioactive molecules. Analyzing cellular protection with libraries of 
compounds targeted against ricin is a key step to study structure-activity relationships. Rapid 
development of these hits into more potent molecules without the use of fastidious chemistry is a 
major technical hurdle. Furthermore, affinity chromatography will often reveal non-obvious interacting 
partners. Once an inhibitor has been immobilized, cell lysates or protein extracts are then passed 
through a column of inhibitor-decorated beads. Proteins that bind very tightly are retained, while  
non-binding proteins are washed away. Bound proteins can be eluted, separated by SDS-PAGE, and 
identified by mass spectrometry. As mentioned above, the main difficulty of this process is the 
inability to isolate proteins with a low binding affinity, because high-stringency washes are required to 
minimize contamination with non-specific proteins. This problem can be circumvented by using a 
covalent cross-linking between the inhibitor and the target protein. Another key determinant of the 
success or failure of affinity chromatography is the abundance of the target protein(s). It is far more 
difficult for a low-abundance protein to be detected above background level, unless the identification 
scheme includes an enrichment step that enhances sensitivity in the MS read-out. To achieve protein 
identification, it is important to work with the same cell line as that used for HTS. We have observed 
that some ricin inhibitors identified by HTS have varying degrees of potency in their protection of 
different cell lines. This might reflect variations in the expression levels of target-proteins among these 
different cell lines. Many variations of affinity-based target identification strategies exist. These 
include, stable isotope labeling with amino acids in cell culture (SILAC), [48]) including genetic 
approaches by phage display, three-hybrid screens [49,50], and drug affinity responsive target stability 
(DARTS) [51]. New ways of creating high-affinity probes from weak inhibitors have also been 
reported, and these are based on linking two low-affinity compounds onto one scaffold to exploit the 
effect of avidity [52,53]. 
4. Conclusions 
The studies that we have reviewed demonstrate the use of cell-based HTS to identify new chemical 
entities that protect cells and mice against ricin. This approach was derived from the observation that 
molecules disrupting the Golgi apparatus, although improper for therapeutic use, protected cells 
against intoxication by ricin and other toxins. The most promising leads target the retrograde pathway. 
Simple and robust tests have been used to screen large libraries; over 100,000 small-compounds have 
been tested so far, resulting in the discovery of less than 10 chemical entities with robust activity 
against the cytotoxic effects of ricin. Although the size of the compound libraries and the number of 
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high-throughput screens targeting retrograde toxins may continue to increase, the difficulty is to select 
the most promising candidates for further exploration. HTS is a very costly process (estimated $0.1 to 
$10 per compound), and the coverage of relevant chemical space needs to be improved by selecting 
new chemical libraries for screens. Besides libraries of bioactive compounds (drugs), most chemical 
libraries used for cell-based HTS come from two different sources: natural resources and synthetic 
chemical libraries. The former has the advantage of a higher structural diversity, whereas the latter 
corresponds to “drug-like” compounds in accordance with the rules of Lipinski [54]. Although these 
rules are useful to assess the risk profile of a drug candidate that is entering development, they do not 
necessarily define the properties of a good lead. Thus, the “quality” of libraries needs to be improved, 
and other filters may be used to select collections for future screens. Furthermore, a virtual screening 
approach could be of interest if the identified compounds described in this review interact with new 
cellular targets. This may save resources and reduce the experimental work involved by suggesting 
limited sets of molecules to be tested. 
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